HIPPURAN I 131 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hippuran I 131, and what generic alternatives are available?
Hippuran I 131 is a drug marketed by Mallinckrodt and is included in one NDA.
The generic ingredient in HIPPURAN I 131 is iodohippurate sodium i-131. Additional details are available on the iodohippurate sodium i-131 profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for HIPPURAN I 131?
- What are the global sales for HIPPURAN I 131?
- What is Average Wholesale Price for HIPPURAN I 131?
Summary for HIPPURAN I 131
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 3 |
| Patent Applications: | 72 |
| DailyMed Link: | HIPPURAN I 131 at DailyMed |
Recent Clinical Trials for HIPPURAN I 131
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Medical Center Groningen | NA |
| Rigshospitalet, Denmark | Phase 1 |
| University of Copenhagen | Phase 1 |
US Patents and Regulatory Information for HIPPURAN I 131
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt | HIPPURAN I 131 | iodohippurate sodium i-131 | INJECTABLE;INJECTION | 016666-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
